Exploring a Screening Tool to Assess PAH Risk in SSc Patients

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Exploring a Screening Tool to Assess PAH Risk in SSc Patients



ReachMD Healthcare Image

    Patients with systemic sclerosis (SSc) can develop PAH at any time, but a screening tool may help minimize missed diagnoses.1,2

    Please See


    • Sponsored by

    • Overview

      Pulmonary arterial hypertension (PAH) is a serious complication that can develop at any time in patients with systemic sclerosis (SSc).1,2 In this video, learn about a screening tool for healthcare professionals treating SSc patients that can help routinely assess PAH risk.2 This practical tool is based on a clinically validated algorithm developed by a team of healthcare professionals, including rheumatologists and cardiologists. The 2022 European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines for the diagnosis and treatment of pulmonary hypertension recommend this algorithm be used to identify asymptomatic PAH in adult patients who have had SSc for more than three years and who are showing signs of declining pulmonary function (including a forced vital capacity equal to or greater than 40 percent and a diffusing capacity of the lungs for carbon monoxide less than 60 percent).2,3 

      1. Hachulla E, Launay D, Mouthon L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis?. CHEST. 2009;136(5):1211-1219.
      2. Coghlan JG, Denton CP, Grünig E, et al. DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340-1349.
      3. Humbert M, Kovacs G, Hoeper M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022:43(38):3618–3731.

      © 2023 Actelion Pharmaceuticals US, Inc. cp-257124v2 05/23


    • DETECT App's Intended Use:

      The DETECT Screening Tool for PAH-SSc was funded and developed by Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company. It is limited for use by healthcare specialists who treat patients with SSc, and who are familiar with PAH as a complication of SSc. It is not intended to replace the medical or professional judgment of healthcare providers. It does not provide professional advice and should not be considered a diagnosis. Healthcare professionals using the tool should exercise clinical judgment as to the information they provide to the patient based upon the tool.

    Schedule30 Sep 2023